Results 51 to 60 of about 72,678 (220)

Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma [PDF]

, 2017
High-grade epithelial ovarian carcinomas (OC) containing mutated BRCA1 or BRCA2 (BRCA1/2) homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and poly(ADP-ribose) polymerase inhibitors (PARPi), while restoration of HR ...
Barker, Holly, Bernstein, Kara A., Botwell, David D.L., Brunette, Gregory J., Coleman, Robert L., Floquet, Anna, Friedlander, Michael, Giordano, Heidi, Harding, Thomas C., Harrell, Maria I., Ho, Gwo-Yaw, Jasin, Maria, Kass, Elizabeth M., Kaufmann, Scott H., Kichenadasse, Ganessan, Kondrashova, Olga, Kuiper, Michael J., Lin, Kevin K., Maloney, Lara, McNeish, Iain A., Nguyen, Minh, O'Malley, David M., Oza, Amit M., Prakash, Rohit, Raponi, Mitch, Robillard, Liliane, Scott, Clare L., Shield-Artin, Kirsty, Simmons, Andrew D., Sullivan, Meghan R., Sun, James X., Swisher, Elizabeth M., Teng, Nelson N.H., Tinker, Anna V., Wakefield, Matthew J.   +34 more
core   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

Urologic Bacteriome: The Hero or the Villain in Prostate Cancer Onset, Progression, and Treatment?

Medicinal Research Reviews, EarlyView.
ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide and the fifth leading cause of cancer‐related mortality, presenting urgent unmet clinical needs in diagnosis and treatment. The recognition of the microbiome as a key factor in human health has prompted numerous studies, revealing an exciting new approach to ...
Lara R. S. Fonseca, Mariana Feijó, Cátia V. Vaz, Bruno J. Pereira, Sandra Laurentino, Ana Palmeira‐de‐Oliveira, Sílvia Socorro   +6 more
wiley   +1 more source

Genetic analysis of primary lung interdigitating dendritic cell sarcomas

The Journal of Pathology, EarlyView.
Abstract Interdigitating dendritic cell sarcomas (IDCSs) are rare tumors that commonly arise in the hematopoietic system and rarely outside. The genetic drivers of IDCS carcinogenesis are unknown; therefore, therapeutic options are limited. We investigated somatic gene mutations and copy‐number alterations (CNAs) in nine IDCSs arising in the lung by ...
Mikhail S Ermakov, Juliana Faria Filipe, Sylvia Eidenhammer, German Ott, Iris Halbwedl, Karl Kashofer, Helmut Popper   +6 more
wiley   +1 more source

Attitudes Toward Prenatal Interventions in the Fanconi Anemia Community

Prenatal Diagnosis, EarlyView.
ABSTRACT Objective In‐utero cell and gene therapies may offer prenatal treatment options for inherited diseases. Preclinical data suggests in‐utero (IU) hematopoietic stem cell transplantation (HSCT) could prevent Fanconi anemia (FA) related bone marrow failure without genotoxic conditioning or immune suppression.
Tony Lum, Catherine Lee, Tippi MacKenzie, Billie Lianoglou, Agnieszka Czechowicz   +4 more
wiley   +1 more source

Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. [PDF]

, 2019
Despite being one of the most common cancers, treatment options for prostate cancer are limited. Novel approaches for advanced disease are needed. We evaluated the relative rate of use of clinical-grade next generation sequencing (NGS) in prostate cancer,
Carter, Jennifer L, Elkin, Sheryl K, Ikeda, Sadakatsu, Kurzrock, Razelle, Tomson, Brett N   +4 more
core  

Evaluation of the current knowledge limitations in breast cancer research: a gap analysis [PDF]

, 2008
BACKGROUND A gap analysis was conducted to determine which areas of breast cancer research, if targeted by researchers and funding bodies, could produce the greatest impact on patients.
A Cox, A Howell, A Kamb, A Maurice, A Moyer, A Renwick, A Rodger, Adrian Harris, AH Eliassen, AH Sims, Alastair Thompson, Angela Cox, Anthony Howell, C Julian-Reynier, C Kuperwasser, CA Purdie, CD Wagner, CH Kroenke, Charles Streuli, CJ Watson, CJ Watson, CM Perou, D Sachdev, DF Easton, Diana Harcourt, DJ Britton, DJ Hunter, DM Abd El-Rehim, DM Harcourt, DS Main, E Amir, E Katz, E Tiligada, G Bon, GP Gui, GW Sledge, H Goulding, HE Huang, Ingunn Holen, International Agency for Research on Cancer Expert Group, IO Ellis, J Bogaerts, J Brennan, J Brett, J Corner, J Debnath, J Polanowska, J Stingl, J Teulière, JJ Dignam, JK Camoriano, JL Jones, JM Bartlett, JM Dixon, JM Gee, JT Scott, Julia Gee, JW Jonker, K Polyak, K Rennstam, KA Green, KE Sleeman, Keith Brennan, KJ Fowler, KL Schwertfeger, KR Brennan, KW Kinzler, L Cortesi, L Fallowfield, L Hennighausen, L Larue, L Lostumbo, LL Northouse, LS Freedman, M Adams, M Harvie, M Harvie, M Shackleton, M Sidani, M Tanner, M Zhang, MD Holmes, MD Sternlicht, MD Sternlicht, Michael Steel, Michelle Harvie, MJ Piccart-Gebhart, ML Asselin-Labat, ML McNeely, ML McNeely, MM Ip, MO Leach, N Barnes, N Rahman, N Sarwar, NG Howlett, P Dent, P Schofield, PA Kenny, R DasGupta, R Doll, R Leake, R Scully, R Serra, RA Walker, RB Clarke, Robert Nicholson, RT Chlebowski, S Anand, S Hiscox, S Seal, S Stylianou, SA Bingham, SE Moody, SJ Cleator, SK Sharan, SN Stacey, SR Johnston, T Sheard, T Sjöblom, T Sorlie, The Breast Cancer Association Consortium, The CHEK2 Breast Cancer Case-Control Consortium, V Aranda, V Speirs, VA McCormack, VG Vogel, WD Foulkes, X Yu, YL Low   +129 more
core   +5 more sources

Intelligent nano‐platforms in breast cancer therapy: Current advances and future perspectives

Precision Medical Sciences, EarlyView.
The smart nano platform in breast cancer treatment is designed with advanced nanocarriers, including liposomes, hydrogels, porous nanoparticles, and aptamer‐based systems. These systems are capable of targeted drug release and response to environmental stimuli.
Tina Rahimi, Moluk Aivazi
wiley   +1 more source

Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in Cypriot population. [PDF]

, 2010
Inability to correctly repair DNA damage is known to play a role in the development of breast cancer. Single nucleotide polymorphisms (SNPs) of DNA repair genes have been identified, which modify the DNA repair capacity, which in turn may affect the risk
Bashiardes, E, Cariolou, MA, Daniel, M, Hadjisavvas, A, Kakouri, E, Loizidou, MA, Marcou, Y, Michael, T, Neuhausen, SL, Newbold, RF   +9 more
core  

Rapid detection of copy number variations and point mutations in BRCA1/2 genes using a single workflow by ion semiconductor sequencing pipeline [PDF]

, 2018
Molecular analysis of BRCA1 (MIM# 604370) and BRCA2 (MIM #600185) genes is essential for familial breast and ovarian cancer prevention and treatment.
Amanti, C, De Marchis, L, Germani, A, Libi, F, Lombardi, A, Maggi, S, Mattei, M, Pellegrini, P, Piane, M, Pizzuti, A, Stanzani., G, Torrisi, Mr   +11 more
core   +1 more source